Category Archives: Adcetris

From Pharm to Market at Seattle Genetics

Once you climb the hill at Bothell’ Cascade Business Park to the global head offices of Seattle Genetics, the cluster of beige apartments does not represent edgy science. However, in the lobby of Building Three, you will come across a green beautiful rectangular monument that speaks a lot for the company. The sculpture, constructed from Lego bricks resembles a human antibody. Since the company was founded in 1998, Seattle Genetics has been doing research on human antibodies. The power of the firm’s antibodies resides in their prowess to connect to their things like therapy. Normally, an antibody delivers a toxic substance into a cancer cell to suppress it from inside.

This is a strategy that helps the Seattle genetics to make it into the big leagues. For the company to become a pharmaceutical firm, the biotech community in Seattle has decided to support it through the up and down cycles that afflicted the sector. Seattle Genetics is an established company that boasts a market value of almost $10 billion and has more than 900 employees. The company ranks as the largest biotech in Washington. Having great ambitions to be listed among the handful of firms that advance from biotech to big Pharm, Seattle Genetics has heavily invested in researching, marketing and anticipates to add 200 extra workers this year.

Adcetris is the major drug produced by the company that is responsible for treating Hodgkin lymphoma, a cancer of the lymph system that spreads to other organs if not treated. If the expensive test that is under way brings positive results, its sales will kick off. Clay Siegall, the president and founder of Seattle Genetics says that his company is an emerging global, multiple oncology companies. He also points that the long list of drugs in the company’s pipeline is a clear evidence of his desire of building a great company.

About Clay Siegall

Dr. Clay Siegall is the Chairman of the Board of Directors. He is the co-founder and CEO of Seattle Genetics that was founded in 1998. Under his governance, the company has managed to build a diverse pipeline of antibody-based cancer therapies.

He has also guided his company is income-generating activities, where he acquired more than $675 million via public and private funding. Before establishing Seattle genetics, Clay Siegel worked at Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. He also worked at the National Cancer Institute and National Institute of Health from 1988 to 1991.